

NCT02301039 comparison:

Summary:
CHIA has 30 criteria while your personal folder has 30 criteria
Total found criteria: 30/30
Total not Found: 0/30
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age ≥ 18 years (Age ≥ 12 years for patients with   │ Age ≥ 18 years (Age ≥ 12 years for patients with   │
│ bone sarcomas)                                     │ bone sarcomas)                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Histologically confirmed diagnosis of              │ Histologically confirmed diagnosis of              │
│ unresectable, recurrent, and/or metastatic high    │ unresectable, recurrent, and/or metastatic high    │
│ grade soft-tissue or bone sarcoma of one of the    │ grade soft-tissue or bone sarcoma of one of the    │
│ following subtypes: soft tissue sarcomas           │ following subtypes: soft tissue sarcomas           │
│ (leiomyosarcoma, poorly differentiated/de-         │ (leiomyosarcoma, poorly differentiated/de-         │
│ differentiated liposarcoma, high grade pleomorphic │ differentiated liposarcoma, high grade pleomorphic │
│ undifferentiated sarcoma/MFH and synovial          │ undifferentiated sarcoma/MFH and synovial          │
│ sarcoma), and bone sarcomas (Ewing sarcoma,        │ sarcoma), and bone sarcomas (Ewing sarcoma,        │
│ osteosarcoma, and chondrosarcoma [de-              │ osteosarcoma, and chondrosarcoma \[de-             │
│ differentiated or mesenchymal])                    │ differentiated or mesenchymal\])                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ ECOG Performance Status of 0 or 1                  │ ECOG Performance Status of 0 or 1                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ At least one site of measurable disease on CT/MRI  │ At least one site of measurable disease on CT/MRI  │
│ scans as defined by RECIST 1.1. Baseline imaging   │ scans as defined by RECIST 1.1. Baseline imaging   │
│ must be performed within 30 days of dosing         │ must be performed within 30 days of dosing         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ At least one site of accessible disease for pre-   │ At least one site of accessible disease for pre-   │
│ and post-treatment core biopsies for at least 20   │ and post-treatment core biopsies for at least 20   │
│ patients per arm on the expansion cohorts          │ patients per arm on the expansion cohorts          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients may have received 1-3 prior systemic      │ Patients may have received 1-3 prior systemic      │
│ therapies in the metastatic setting                │ therapies in the metastatic setting                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate organ function within 14 days of dosing   │ Adequate organ function within 14 days of dosing   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must be willing to provide and have available      │ Must be willing to provide and have available      │
│ archival tissue for PD-L1 testing                  │ archival tissue for PD-L1 testing                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Written, voluntary informed consent                │ Written, voluntary informed consent                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fertile men and women of childbearing potential    │ Fertile men and women of childbearing potential    │
│ must agree to use an effective method of birth     │ must agree to use an effective method of birth     │
│ control from providing signed consent and for 120  │ control from providing signed consent and for 120  │
│ days after last study drug administration. Women   │ days after last study drug administration. Women   │
│ of childbearing potential include pre-menopausal   │ of childbearing potential include pre-menopausal   │
│ women and women within the first 2 years of the    │ women and women within the first 2 years of the    │
│ onset of menopause. Women of childbearing          │ onset of menopause. Women of childbearing          │
│ potential must have a negative pregnancy test ≤ 72 │ potential must have a negative pregnancy test ≤ 72 │
│ hours prior to Day 1 of study                      │ hours prior to Day 1 of study                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Effective methods of birth control include:        │ Effective methods of birth control include:        │
│ surgically sterile, barrier device (condom,        │ surgically sterile, barrier device (condom,        │
│ diaphragm), contraceptive coil, intrauterine       │ diaphragm), contraceptive coil, intrauterine       │
│ device (IUD), and abstinence                       │ device (IUD), and abstinence                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy of >12 weeks                       │ Life expectancy of \>12 weeks                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with central nervous system disease are   │ Patients with central nervous system disease are   │
│ eligible for enrollment if they have received      │ eligible for enrollment if they have received      │
│ prior radiotherapy or surgery to sites of CNS      │ prior radiotherapy or surgery to sites of CNS      │
│ metastatic disease and are without evidence of     │ metastatic disease and are without evidence of     │
│ clinical progression for at least 4 weeks prior to │ clinical progression for at least 4 weeks prior to │
│ screening, have no evidence of new or enlarging    │ screening, have no evidence of new or enlarging    │
│ brain metastases, and are off steroids for at      │ brain metastases, and are off steroids for at      │
│ least 7 days before first dose of pembrolizumab    │ least 7 days before first dose of pembrolizumab    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior systemic therapy targeting PD-1: PD-L1 axis  │ Prior systemic therapy targeting PD-1: PD-L1 axis  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who are curable by conventional           │ Patients who are curable by conventional           │
│ multidisciplinary management                       │ multidisciplinary management                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with severe and/or uncontrolled           │ Patients with severe and/or uncontrolled           │
│ concurrent medical disease that in the opinion of  │ concurrent medical disease that in the opinion of  │
│ the investigator could cause unacceptable safety   │ the investigator could cause unacceptable safety   │
│ risks or compromise compliance with the protocol   │ risks or compromise compliance with the protocol   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have received wide field radiotherapy │ Patients who have received wide field radiotherapy │
│ ≤ 4 weeks or limited field radiation for           │ ≤ 4 weeks or limited field radiation for           │
│ palliation < 2 weeks prior to screening or who     │ palliation \< 2 weeks prior to screening or who    │
│ have not recovered adequately from side effects of │ have not recovered adequately from side effects of │
│ such therapy                                       │ such therapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have active infections requiring      │ Patients who have active infections requiring      │
│ therapy                                            │ therapy                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients that are known to be positive for Human   │ Patients that are known to be positive for Human   │
│ Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), │ Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), │
│ active Hepatitis B (HBsAg reactive), or Hepatitis  │ active Hepatitis B (HBsAg reactive), or Hepatitis  │
│ C (HCV RNA [qualitative] is detected); patients    │ C (HCV RNA \[qualitative\] is detected); patients  │
│ with negative Hepatitis C antibody testing may not │ with negative Hepatitis C antibody testing may not │
│ need RNA testing                                   │ need RNA testing                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients that have a known psychiatric or          │ Patients that have a known psychiatric or          │
│ substance abuse disorder that would interfere with │ substance abuse disorder that would interfere with │
│ cooperation with the requirements of the trial     │ cooperation with the requirements of the trial     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who received systemic anti-cancer         │ Patients who received systemic anti-cancer         │
│ treatment prior to the first dose of study drug    │ treatment prior to the first dose of study drug    │
│ within the following time frames                   │ within the following time frames                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with active autoimmune disease or a       │ Patients with active autoimmune disease or a       │
│ documented history of autoimmune disease or        │ documented history of autoimmune disease or        │
│ syndrome that requires systemic steroids or        │ syndrome that requires systemic steroids or        │
│ immunosuppressive agents. Patients with vitiligo   │ immunosuppressive agents. Patients with vitiligo   │
│ or resolved childhood asthma/atopy would be        │ or resolved childhood asthma/atopy would be        │
│ exception to this rule. Patients that require      │ exception to this rule. Patients that require      │
│ inhaled steroids or local steroid injections would │ inhaled steroids or local steroid injections would │
│ not be excluded from the study. Patients with      │ not be excluded from the study. Patients with      │
│ hypothyroidism not from autoimmune disease that is │ hypothyroidism not from autoimmune disease that is │
│ stable on hormone replacement will not be excluded │ stable on hormone replacement will not be excluded │
│ from the study                                     │ from the study                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant or nursing/breastfeeding    │ Women who are pregnant or nursing/breastfeeding    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to pembrolizumab or another │ Known hypersensitivity to pembrolizumab or another │
│ mAb                                                │ mAb                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has a history of (non-infectious) pneumonitis that │ Has a history of (non-infectious) pneumonitis that │
│ required steroids or current pneumonitis           │ required steroids or current pneumonitis           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with untreated central nervous system     │ Patients with untreated central nervous system     │
│ disease. Patients with controlled treated CNS      │ disease. Patients with controlled treated CNS      │
│ lesions who have undergone surgery or stereotactic │ lesions who have undergone surgery or stereotactic │
│ radiosurgery and stable for 4 weeks are eligible   │ radiosurgery and stable for 4 weeks are eligible   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to comply with protocol required         │ Inability to comply with protocol required         │
│ procedures                                         │ procedures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with medical conditions that require      │ Patients with medical conditions that require      │
│ chronic systemic corticosteroid therapy or require │ chronic systemic corticosteroid therapy or require │
│ any other form of immunosuppressive medication.    │ any other form of immunosuppressive medication.    │
│ However, patients using physiologic replacement    │ However, patients using physiologic replacement    │
│ doses of hydrocortisone, or its equivalent, will   │ doses of hydrocortisone, or its equivalent, will   │
│ be considered eligible for this study: up to 20 mg │ be considered eligible for this study: up to 20 mg │
│ hydrocortisone (or 5 mg of prednisone) in the      │ hydrocortisone (or 5 mg of prednisone) in the      │
│ morning and 10 mg hydrocortisone (or 2.5 mg        │ morning and 10 mg hydrocortisone (or 2.5 mg        │
│ prednisone) in the evening                         │ prednisone) in the evening                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with the risk factors for bowel           │ Patients with the risk factors for bowel           │
│ obstruction or bowel perforation (examples include │ obstruction or bowel perforation (examples include │
│ but not limited to a history of acute              │ but not limited to a history of acute              │
│ diverticulitis, intra-abdominal abscess, abdominal │ diverticulitis, intra-abdominal abscess, abdominal │
│ carcinomatosis)                                    │ carcinomatosis)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have received a live vaccine within   │ Patients who have received a live vaccine within   │
│ 30 days prior to the first dose of trial treatment │ 30 days prior to the first dose of trial treatment │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 12 Years │
╘═══════════════════════════════════╛